Trials / Completed
CompletedNCT02261220
A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 380 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with select advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MEDI4736 | MEDI4736 is administered by IV infusion in combination with tremelimumab |
| BIOLOGICAL | tremelimumab | Tremelimumab is administered by IV infusion in combination with MEDI4736 |
Timeline
- Start date
- 2014-10-13
- Primary completion
- 2020-01-27
- Completion
- 2020-01-27
- First posted
- 2014-10-10
- Last updated
- 2020-03-06
Locations
75 sites across 9 countries: United States, Canada, France, Germany, Israel, Netherlands, South Korea, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02261220. Inclusion in this directory is not an endorsement.